Rethinking Severity Assessment in Alopecia Areata

Although hair loss is the most visible manifestation of alopecia areata (AA), clinicians increasingly recognize AA as a systemic, immune-mediated condition with consequences that extend far beyond the scalp. Patients often present with fluctuating disease activity, unpredictable progression, and profound psychosocial distress that is not reliably captured by surface-level assessments alone.

At 3 recent Dermatology Times Case-Based Roundtable® events, Natasha A. Mesinkovska, MD, PhD; Karan Lal, DO, MS, FAAD; and Arash Mostaghimi, MD, MPH, FAAD, moderated discussions with dermatology clinicians in attendance to review 3 patient cases of AA and Janus kinase (JAK) inhibitor use. Each group discussed how emerging systemic therapies—particularly JAK inhibitors—are reshaping real-world management. Rather than focusing on individual presentations, discussions centered on shared clinical challenges: assessing disease severity, determining when to escalate therapy, integrating clinical trial data into practice, and aligning treatment strategies with patient-defined goals.

Mesinkovska is an associate professor and vice chair for clinical research in the Department of Dermatology at the University of California, Irvine; Lal is a double board-certified pediatric and cosmetic dermatologist at Affiliated Dermatology in Scottsdale, Arizona; and Mostaghimi is an assistant professor of dermatology, director of the inpatient dermatology consult service, and codirector of the Complex Medical Dermatology Fellowship at Brigham and Women’s Hospital in Boston, Massachusetts.

Across the discussions, moderators agreed that effective AA management requires a shift away from rigid algorithms toward a more patient-centered framework—one that integrates clinical measures, quality-of-life considerations, and evolving therapeutic data.

Disease Burden Beyond Hair Loss

AA is often minimized as a cosmetic condition, yet attendees at the roundtable emphasized that its impact is frequently disproportionate to the extent of visible hair loss. Patients may experience anxiety, depression, social withdrawal, and impaired work or academic performance because of its effect on facial identity and daily social interactions.

Mesinkovska agreed: “Eyebrows, eyelashes, facial hair…I never knew how much it mattered to people. Apparently, it matters a lot,” she said. “In the trials, we actually had people who would stay on these medications for years, just for eyebrows and eyelashes.”

The chronic and unpredictable nature of AA further compounds disease burden. Patients may oscillate between periods of regrowth and relapse, eroding confidence in therapy and increasing emotional distress. As Mesinkovska noted during the discussion, “Patients are not just reacting to what they see today—they’re living with the fear of what could happen next.”

Identifying and Assessing Disease Severity

Severity assessment remains a foundational yet imperfect component of AA management. The Severity of Alopecia Tool (SALT) score continues to serve as the standard clinical metric, offering a reproducible measure of scalp hair loss. However, the moderators consistently emphasized its limitations when used in isolation.

Moderators noted that loss of facial hair can be especially destabilizing, often driving treatment escalation even when scalp involvement appears limited. One attendee remarked that patients may tolerate patchy scalp loss but struggle profoundly with eyebrow or eyelash loss.

SALT scoring does not account for facial hair involvement, rate of progression, disease chronicity, or psychosocial impact—all of which influence treatment decisions in daily practice. Several attendees noted that a patient with a SALT score of 30 and eyebrow involvement may warrant systemic therapy sooner than a patient with more extensive but less distressing scalp disease.

The Alopecia Areata Scale (AASc) is another assessment method that was discussed, with categories defined as follows:

• Mild: 20% or less scalp hair loss
• Moderate: 21% to 49% scalp hair loss
• Severe: 50% or greater scalp hair loss

Dynamic assessment over time was viewed as critical. Rapid progression, positive hair pull tests, and worsening SALT or AASc scores over short intervals were frequently cited as red flags prompting escalation. Moderators agreed that severity is best understood as a composite of objective findings and subjective burden rather than a single numeric threshold.

Conclusion

Across the roundtable discussions, a consistent message emerged: Effective AA management demands early recognition of disease burden, thoughtful assessment of severity, and individualized integration of systemic therapies. As therapeutic options continue to expand, clinicians are increasingly equipped to offer meaningful regrowth and improved quality of life for patients who previously had few effective choices.

Although challenges remain—including long-term disease control and access to therapy—the evolving systemic landscape offers renewed opportunity to address AA as the complex chronic disease it is. The discussions underscored that success in AA is not defined solely by hair regrowth but by restoring confidence, function, and hope for patients navigating this unpredictable condition.